Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2027

Conditions
Brain Tumor
Interventions
DRUG

Panitumumab-IRDye800

Panitumumab-IRDye800 is an imaging agent prepared as a drug-dye compound from panitumumab (Vectibix), a fully-humanized IgG2 monoclonal anti-epidermal growth factor receptor (EGFR) antibody, and IRDye800CW dye. Panitumumab-IRDye800 delivered intravenous (IV).

DEVICE

Pinpoint-IR9000 endoscopic/handheld device

"Novadaq intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."

DEVICE

Explorer Air camera

"Surgvision intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."

DEVICE

PDE-NEO-II

"Hamamatsu Photonics KK intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."

Trial Locations (1)

94304

Stanford Cancer Center, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT04085887 - Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures | Biotech Hunter | Biotech Hunter